521 related articles for article (PubMed ID: 31413009)
1. The Immunoscore: Colon Cancer and Beyond.
Angell HK; Bruni D; Barrett JC; Herbst R; Galon J
Clin Cancer Res; 2020 Jan; 26(2):332-339. PubMed ID: 31413009
[TBL] [Abstract][Full Text] [Related]
2. Two immune-enhanced molecular subtypes differ in inflammation, immune checkpoints, mutations, and prognostic outcome in stage I-II colonic carcinoma.
Tang D; Huang W; Yang Z; Wu X; Sang X; Wang K; Cao G; Hao M
J Biochem Mol Toxicol; 2021 Apr; 35(4):e22703. PubMed ID: 33410236
[TBL] [Abstract][Full Text] [Related]
3. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
4. Usefulness and robustness of Immunoscore for personalized management of cancer patients.
Marliot F; Pagès F; Galon J
Oncoimmunology; 2020 Oct; 9(1):1832324. PubMed ID: 33194318
[TBL] [Abstract][Full Text] [Related]
5. The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Zeitoun G; Sissy CE; Kirilovsky A; Anitei G; Todosi AM; Marliot F; Haicheur N; Lagorce C; Berger A; Zinzindohoué F; Galon J; Scripcariu V; Pagès F
Chirurgia (Bucur); 2019; 114(2):152-161. PubMed ID: 31060646
[TBL] [Abstract][Full Text] [Related]
6. The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions.
Pagès F; Taieb J; Laurent-Puig P; Galon J
Oncoimmunology; 2020 Aug; 9(1):1812221. PubMed ID: 32939329
[TBL] [Abstract][Full Text] [Related]
7. Immunoscore and its introduction in clinical practice.
Galon J; Lanzi A
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):152-161. PubMed ID: 32107902
[TBL] [Abstract][Full Text] [Related]
8. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001
[TBL] [Abstract][Full Text] [Related]
9. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
Tauriello DVF; Palomo-Ponce S; Stork D; Berenguer-Llergo A; Badia-Ramentol J; Iglesias M; Sevillano M; Ibiza S; Cañellas A; Hernando-Momblona X; Byrom D; Matarin JA; Calon A; Rivas EI; Nebreda AR; Riera A; Attolini CS; Batlle E
Nature; 2018 Feb; 554(7693):538-543. PubMed ID: 29443964
[TBL] [Abstract][Full Text] [Related]
10. The consensus immunoscore: toward a new classification of colorectal cancer.
Lanzi A; Pagès F; Lagorce-Pagès C; Galon J
Oncoimmunology; 2020 Jul; 9(1):1789032. PubMed ID: 32934885
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
13. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.
Galon J; Fox BA; Bifulco CB; Masucci G; Rau T; Botti G; Marincola FM; Ciliberto G; Pages F; Ascierto PA; Capone M
J Transl Med; 2016 Sep; 14():273. PubMed ID: 27650038
[TBL] [Abstract][Full Text] [Related]
14. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer.
Wu T; Wu X; Wang HY; Chen L
Cancer Commun (Lond); 2019 Apr; 39(1):21. PubMed ID: 30999966
[TBL] [Abstract][Full Text] [Related]
15. An immune infiltration signature to predict the overall survival of patients with colon cancer.
Peng D; Wang L; Li H; Cai C; Tan Y; Xu B; Le H
IUBMB Life; 2019 Nov; 71(11):1760-1770. PubMed ID: 31301220
[TBL] [Abstract][Full Text] [Related]
16. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
17. Tumor Immunology and Tumor Evolution: Intertwined Histories.
Galon J; Bruni D
Immunity; 2020 Jan; 52(1):55-81. PubMed ID: 31940273
[TBL] [Abstract][Full Text] [Related]
18. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
Brockwell NK; Parker BS
Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
20. Discovery and application of immune biomarkers for hematological malignancies.
Zafeiris D; Vadakekolathu J; Wagner S; Pockley AG; Ball GR; Rutella S
Expert Rev Mol Diagn; 2017 Nov; 17(11):983-1000. PubMed ID: 28927305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
